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Abstract
Recent research in autism spectrum disorder (ASD) has aroused interest in anterior cingulate cortex and in the
neurometabolite glutamate. We report two studies of pregenual anterior cingulate cortex (pACC) in pediatric ASD. First, we
acquired in vivo single-voxel proton magnetic resonance spectroscopy (1H MRS) in 8 children with ASD and 10 typically
developing controls who were well matched for age, but with fewer males and higher IQ. In the ASD group in midline pACC,
we found mean 17.7% elevation of glutamate + glutamine (Glx) (p,0.05) and 21.2% (p,0.001) decrement in creatine +
phosphocreatine (Cr). We then performed a larger (26 subjects with ASD, 16 controls) follow-up study in samples now
matched for age, gender, and IQ using proton magnetic resonance spectroscopic imaging (1H MRSI). Higher spatial
resolution enabled bilateral pACC acquisition. Significant effects were restricted to right pACC where Glx (9.5%, p,0.05), Cr
(6.7%, p,0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p,0.01) in the ASD sample were elevated
above control. These two independent studies suggest hyperglutamatergia and other neurometabolic abnormalities in
pACC in ASD, with possible right-lateralization. The hyperglutamatergic state may reflect an imbalance of excitation over
inhibition in the brain as proposed in recent neurodevelopmental models of ASD.
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Introduction
Proposed abnormal glutamate (Glu) metabolism in autism
spectrum disorder (ASD) [1–7] is supported by several lines of
evidence. Epilepsy is common in ASD [8] and epileptic seizures
are propagated by excitatory Glu. Elevated Glu and other
excitatory amino acids have been reported in blood serum,
plasma, and platelets in ASD [9–13]. Post-mortem neuropathol-
ogy in ASD has found elevated mRNA or protein levels of
glutamatergic transporters and neurotransmitter receptors [14].
And finally, ASD has been associated with single-nucleotide
polymorphisms (SNPs) in glutamatergic genes, including those
coding for transporters [15], metabotropic and ionotropic
receptors [3,16,17], the enzyme glutamate decarboxylase [18],
and the mitochondrial aspartate/glutamate carrier [19–26]. The
last listed is also supported by neuropathology [27]. These various
linkages give ample reason to ask if brain levels of Glu and related
metabolites are disturbed in ASD and if such abnormalities have a
bearing on clinical presentation. Neuroimaging assays of regional
levels of these compounds may help evaluate glutamatergic
theories of ASD and inform potential therapies targeting Glu in
specific brain structures.
Proton magnetic resonance spectroscopy (1H MRS) is a
neuroimaging technique that measures in vivo brain Glu safely
and non-invasively in children. Thereby, ‘‘Glx’’, the combined
signal for Glu and spectrally overlapping glutamine (Gln), is often
more reliably assayed than Glu alone, especially at low field (,3
T). MRS investigations of autistic spectrum disorders have been
numerous [28–52], but few have reported Glu or Glx
[28,31,32,35,47,53]. All of these studies detected evidence of
glutamatergic abnormalities except Friedman et al.[31,32], who
examined very young (,5 years old) children with ASD. This
suggests that further exploration of regional Glu and Glx in the
brain in ASD is warranted.
One brain region frequently implicated in ASD, but where
glutamatergic metabolites have been little explored [53], is the
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anterior cingulate cortex. Evidence from several investigative
modalities points to involvement of the anterior cingulate in ASD,
including neuropathology [54–57], structural MRI [58–62], fMRI
[63–67], MRS [33,42,46,53], PET [68,69], SPECT [70], and
EEG evoked potentials [71]. One hypothesis also relates anterior
cingulate dysfunction to deficits in joint attention and social
orienting in ASD [72]. This plentiful prior work gives reason to
search for further abnormalities, perhaps involving the glutama-
tergic system, in anterior cingulate. Here, we report on two
independent studies of glutamatergic neurometabolites in the
anterior cingulate cortex in pediatric ASD; the first a pilot study,
the second a larger follow-up investigation.
Within the cingulate gyrus, our investigations focused on the
pregenual anterior cingulate cortex (pACC) subregion, one of the
eight subregions in Vogt’s definitive parcellation of the human
cingulate cortex [73,74]. Most of the above-cited neuroimaging
studies localized their acquisition or analysis volumes based on the
older four-subregion or two-subregion cingulate models. As the
eight-subregion model is most consistent with extant neuropath-
ological, neuroimaging, and neurocognitive data, we anticipated
that focusing on a subregion within this model would improve
odds of detecting Glx effects and would permit more anatomically
standardized statement of our results. Moreover, recent neuroim-
aging investigations, including multimodal MRS-fMRI and
combined fMRI and genetic work, of autistic symptoms and
autistic traits in healthy subjects have demonstrated focal effects
within the pACC, raising the possibilities for finding MRS effects
there as well [65,66,75,76].
Experiment 1
The first experiment was a pilot study targeting possible
abnormalities in Glx in ASD in the pACC. The midline (left +
right) pACC was sampled using single-voxel MRS.
Methods
Eight high-functioning subjects with ASD (1 female; mean 6
SD age: 11.262.6 years, range: 7.8–15.9 years) and 10 typically
developing control subjects (5 female; 13.262.5 years, 7.4–
16.5 years) free of developmental or psychiatric disorder partic-
ipated (Table 1). Seven subjects with ASD met criteria for autism
and one subject met criteria for PDD-NOS according to the
Autism Diagnostic Interview Revised (ADI-R) and the Autism
Diagnostic Observation Schedule (ADOS) [77–78]. These stan-
dardized instruments were administered by study personnel
trained to reliability by Dr. Catherine Lord’s research group.
Exclusionary criteria included the presence of major medical or
neurologic illness, including epilepsy, and presence of a known
genetic syndrome associated with autism such as Fragile X.
Control subjects were recruited from local community schools. All
subjects were screened for neurological, language, hearing or
psychiatric disorders by K-SADS-PL interview with the parent
[79]. Exclusion criteria for healthy controls included any lifetime
significant medical or Axis I mental disorder. The two subject
samples did not differ significantly in age. One subject with ASD
was on fluoxetine, two were on methylphenidate, and the
remaining subjects were receiving no psychoactive medication at
time of scan. No controls were undergoing neuropharmacologic
treatment at time of MRS. Mean full-scale IQ (Wechsler
Intelligence Scale for Children – WISC) [80] was 90.0611.5
(74–105) for the sample with ASD and 112.3618.5 (83–137) for
the control sample, a significant difference (p,0.05, independent
T-test of rank-transformed data). The study was approved by the
UCLA Human Subjects Review Board and we obtained written,
informed consent from all subjects or from the subjects’ parents or
guardians.
MRI and single-voxel 1H MRS were acquired contemporane-
ously at 1.5 T on a GE Signa 56 system with a quadrature head
coil. After sagittal scout, a whole-brain axial fast spin-echo MRI
yielding proton density-weighted images and a coronal T1-
weighted MRI (brain stem and forward) were acquired. These
two MRI volumes were used to position single-voxel water-
suppressed point-resolved spectroscopy (PRESS) 1H MRS (GE
PROBE, repetition time [TR] = 1500 ms, echo-time [TE]
= 25 ms, number of excitations = 256) in midline pACC (Fig. 1) in
order to assess potential group differences in local metabolite
levels. Voxel position and volume (2.4–3.6 cc, 12–15 mm on a
side) were varied to maximize gray-matter content. This procedure
was applied identically for subjects with ASD and controls by
operators blinded to subject diagnosis. The pACC was identified
on MRI as the cingulate cortex directly rostral to the genu of the
corpus callosum where the posterior wall of the MRS voxel was
placed. Each scan was examined post-acquisition. When quality
was low, the scan was repeated. Total session time was 1–
1.5 hours. One subject with ASD was sedated with intravenous
propofol during acquisition. Results for this subject did not differ
markedly from those of the other subjects with ASD. In a separate
MR session, a sagittal whole-brain volumetric acquisition was
performed using a spoiled gradient recalled echo (SPGR) sequence
(TR = 24 ms, TE = 9 ms, number of excitations = 2, in-plane
resolution = 0.9460.94 mm2, partition thickness = 1.2 mm),
yielding T1-weighted images used for MRI tissue-segmentation.
Operators were blinded to subject identity during MRS and
MRI post-processing. MRS PROBE data were processed auto-
matically with LCModel [81]. LCModel yielded absolute levels in
Institutional Units (IU) scaled to water and accounting for variable
voxel volume for five major metabolite peaks. The first peak
represented the sum of the (very closely overlapping) signals for N-
acetyl-aspartate (NAA) and N-acetyl-aspartyl-glutamate (NAAG);
the sum is referred to as ‘‘total NAA’’, abbreviated ‘‘tNAA’’. The
second peak, ‘‘Glx’’, was for the sum of glutamate and glutamine.
The third was for the sum of creatine and phosphocreatine,
together abbreviated ‘‘Cr’’. The fourth was for the sum of the
choline-containing compounds phosphocholine, glycerophospho-
choline, choline proper, and acetylcholine, together abbreviated
‘‘Cho’’. The final peak was for the sugar myo-inositol (‘‘mI’’).
Table 1. Experiment 1: Subject group characteristics.
group gender age, years full-scale IQ medication
ASD 7 male, 1 female 11.262.6 (7.8–15.9) 90.0±11.5* (74–105) 1 fluoxetine, 2
methylphenidate
Typically developing 5 male, 5 female 13.262.5 (7.4–16.5) 112.3618.5 (83–137) None
*p,0.05 vs. controls; values for age and IQ are group mean 6 standard deviation (range).
doi:10.1371/journal.pone.0038786.t001
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Numerous weaker resonances, in particular lipids and macromol-
ecules, were included in the fit. Analyses were restricted to spectra
with linewidth (full-width at half-maximum) #0.10 ppm and with
signal-to-noise ratio $5 and to metabolite peaks that passed the
widely applied standard LCModel automated quality control
criterion SD#20%, supplemented by operator inspection. SPGR-
derived T1-weighted MRI volumes were tissue-segmented into
gray matter, white matter, and CSF whole-brain component
volumes [82] then co-registered into the axial plane of the fast
spin-echo MRI, which was already in register with the MRS
voxels. A home-written software program in the Interactive Data
Language (IDL; Research Systems Inc., Boulder, CO) then
extracted volume% gray matter, white matter, and CSF in each
MRS voxel. LCModel absolute metabolite levels were then
corrected for volume% CSF. Metabolite levels were not corrected
for T1- or T2-relaxation.
Given the small number of subjects, data were rank-transformed
to provide for non-parametric statistical analyses. MRS voxel
tissue composition (volume% gray matter, white matter, CSF) was
compared between groups using independent T-test of rank-
transformed data. CSF-corrected levels of each metabolite were
compared between groups using analysis of covariance (AN-
COVA) of rank-transformed data with subject gender as covariate.
At sites where tissue composition differed significantly between
groups, the relevant volume% variable(s) were added as covariates
to ANCOVA. Criterion for statistical significance was p,0.05,
Bonferroni-corrected for multiple comparisons with numbered a
priori hypotheses. Effects were hypothesized on metabolites in the
following order: 1. Glx, 2. tNAA, 3. Cr, 4. Cho, 5. mI.
Results and Discussion
MRS voxel volume% ranged 74.1–93.9% for gray matter, 3.0–
20.4% for white matter, and 0.1–13.7% for CSF (Table 2).
Volume% white matter in pACC was significantly lower in
subjects with ASD (6.462.2%) than in controls (10.864.2%;
p,0.05); otherwise tissue composition did not differ significantly
between groups.
Fig. 2 shows sample LCModel-fitted 1H MR spectra for a
subject from the sample with ASD and a control subject. To the
naked eye the Glx peak is larger in the subject with ASD than in
the control. High Glx levels were also seen in most of the other
subjects with ASD (Fig. 3). Table 2 lists group-mean CSF-
corrected LCModel-derived metabolite values in pACC. For
subjects with ASD vs. typically-developing controls, ANCOVA
covarying for gender and volume% white matter found signifi-
cantly higher Glx (17.7%; p,0.05) and significantly lower Cr
(21.2%; p,0.05; Fig. 3). No significant effects were found for any
other metabolite. Glx was above the control mean for 7 of 8
subjects with ASD. Upon removing subjects on medication, the
single-voxel MRS Glx elevation in pACC was still significant
(23.2%, p,0.05).
This pilot single-voxel MRS investigation of glutamatergic
metabolites in pACC yielded two findings: 1) Glx was consistently
higher in subjects with ASD than in typically-developing control
subjects and 2) Cr was lower in subjects with ASD than in controls.
These findings suggest that abnormal physiology of the anterior
cingulate in ASD may include disturbances in Glu or Cr
neurometabolism and signal the pACC as one locus of abnormal-
ity within the cingulate gyrus.
The first finding was elevated Glx ( = Glu + Gln) in the pACC.
This supports the notion of glutamatergic disturbances in ASD [1–
7] and favors proposals of hyper- as opposed to hypoglutama-
tergia, at least in the pACC. Glu is normally the larger component
of the Glx signal and is present in tissue in both neurotransmitter
and metabolic pools, which cannot be distinguished by in vivo 1H
MRS [83]. Mechanisms that might increase the combined Glu +
Gln = Glx concentration include greater pre-synaptic vesicular
release of Glu and co-localized NAAG [84], faster breakdown of
NAAG into NAA and Glu [85], and net production rather than
consumption of Glu by the Krebs Cycle in neurons and astrocytes
[86], slower conversion of Gln to GABA [87], and net production
rather than consumption of Gln by the Krebs Cycle. Moreover,
Gln is exported from the astrocyte by the SNAT3 [88] neutral
amino acid membrane transporter, crosses extracellular fluid, and
Figure 1. Axial-oblique spin-echo MRI of the brain at level of
the basal ganglia showing position of midline pregenual
anterior cingulate (pACC) proton magnetic resonance spec-
troscopy voxel (white box). Experiment 1.
doi:10.1371/journal.pone.0038786.g001
Table 2. Experiment 1: Voxel tissue content and proton
magnetic resonance spectroscopy (1H MRS) metabolite levels
in midline pregenual anterior cingulate cortex (pACC) voxel.
ASD Healthy Control
mean ± SD range mean ± SD range
Vol% GM 88.964.1 83.3–93.9 83.965.6 74.1–89.6
Vol% WM 6.4±2.2* 3.0–10.2 10.864.3 4.4–20.4
Vol% CSF 4.763.1 1.8–10.7 5.164.4 0.1–13.7
tNAA 7.461.6 4.6–9.7 7.561.1 6.4–9.5
Glx 17.0±1.4* 14.7–19.2 14.563.0 9.4–18.8
Cr 4.4±0.8* 2.8–5.4 5.660.7 4.7–6.7
Cho 1.160.2 0.8–1.4 1.260.3 0.9–1.9
mI 3.760.4 3.3–4.5 4.460.9 3.0–5.7
*p,0.05 vs. controls controls analysis-of-covariance covarying gender and vol%
WM on rank-transformed (non-parametric) data, Bonferroni-corrected for
multiple comparisons with a priori hypotheses.
SD = standard deviation, GM = gray matter, WM = white matter, CSF =
cerebrospinal fluid.
tNAA = N-acetyl-aspartate + N-acetyl-aspartyl-glutamate, Glx = glutamate +
glutamine, Cr = creatine + phosphocreatine, Cho = choline compounds, mI =
myo-inositol.
doi:10.1371/journal.pone.0038786.t002
Anterior Cingulate Glutamate in ASD
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is taken into the neuron by the SNAT1 transporter [89]. Slowing
of this Gln transport resulting in longer residence times in the Glu-
Gln Cycle [86,90,91] would also lead to higher effective Glx levels.
Consequences of chronic excess Glx could include abnormal
development, ongoing excitotoxic cell damage (particularly in the
case of Glu in the neurotransmitter pool), and inefficient utilization
of cell energy.
The second finding was diminished Cr in the pACC. Creatine
and phosphocreatine are principal reactants in the cellular buffer
for maintenance and rapid mobilization of ATP energy [92–94].
This Cr deficit, along with the above Glx excess and previously
demonstrated 18FDG-PET abnormalities in ASD [95], may reflect
locally aberrant cell-energy metabolism.
Results will be compared, in conjunction with those of
Experiment 2, to previous MRS investigations in a combined
discussion below.
This pilot investigation had a small number of subjects. Subjects
with ASD were compared to a control group that was not well
matched for gender or IQ. Three subjects with ASD were
receiving regular psychotropic medication and one underwent
sedation during the MRS scan; no controls underwent such
pharmacologic treatments. Left and right pACC were sampled
together in a single MRS voxel; that voxel contained, on average
more white matter in subjects with ASD than in controls (although
vol% white matter was under 10% in most subjects and was
covaried for statistically). Despite these limitations, Experiment 1
gives a strong indication (7 of 8 subjects) of above-normal
glutamatergic compounds in the pACC in ASD. Experiment 2
attempted to address some of the above limitations.
Experiment 2
The second experiment was a larger study that again targeted
Glx in ASD in the pACC. This time, the higher spatial resolution
of the proton magnetic resonance spectroscopic imaging (1H
MRSI) technique allowed us to examine left and right pACC
Figure 2. Raw (light gray), fit (heavy solid red), and baseline (solid gray) LCModel (Provencher 2001) output spectra for proton
magnetic resonance spectroscopy voxels placed in midline pregenual anterior cingulate (pACC) in study subject with ASD (left) and
control subject (right). Note larger Glx peak (2.0–2.5 ppm) in subject with ASD. Seven of 8 subjects with ASD exhibited Glx levels above the control
mean (Fig. 3). Experiment 1.
doi:10.1371/journal.pone.0038786.g002
Figure 3. LCModel-derived absolute metabolite levels in Institutional Units (IU) corrected for voxel CSF-content for subjects with
ASD (red triangles) and healthy controls (green squares). Horizontal bars denote group means. Values are shown for glutamate + glutamine
(‘‘Glx’’; left) and creatine + phosphocreatine (right) in pACC. Note elevated Glx and deptressed Cr + PCr in subjects with ASD. *p,.05, **p,.01
(independent T-test following ANCOVA of rank-transformed, therefore non-parametric data.) Experiment 1.
doi:10.1371/journal.pone.0038786.g003
Anterior Cingulate Glutamate in ASD
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separately, and therefore permitted us to investigate any lateral-
ized effects on glutamatergic metabolites in this region. MRSI
furthermore enabled us to investigate the possibility that results of
Experiment 1 were influenced by white-matter intrusion into the
MRS voxel by additionally obtaining metabolite levels in the
prefrontal white-matter regions laterally adjacent to left and right
pACC. Subjects with ASD were now compared to typically
developing control subjects who were matched for age, gender,
and IQ. Based on the results of Experiment 1, we hypothesized
elevated Glx and diminished Cr in ASD in pACC, without any
preference for the left or right hemisphere.
Methods
Twenty-six high-functioning subjects with ASD (7 female; mean
6 SD age: 10.263.3 years, range: 6.1–17.5 years) and 16 typically
developing control subjects (5 female; 11.863.0 years, 7.3–
16.6 years) participated (Table 3). No subject in Experiment 2
was also a subject in Experiment 1. As in Experiment 1,
exclusionary criteria included the presence of major medical or
neurologic illness, including epilepsy, and presence of a known
genetic syndrome associated with autism such as Fragile X.
Subjects with ASD were recruited from the Autism Genetic
Research Exchange (AGRE) and were included only if they had
met criteria for ASD based upon the Autism Diagnostic Interview-
Revised (ADI-R) [77] interview and Autism Diagnostic Observa-
tion Schedule administered by AGRE personnel. All subjects met
criteria for autism according to the ADI-R and seventeen met
criteria for autism and eight for ASD according to the ADOS. Five
subjects with ASD were being treated with stimulants (2
methylphenidate, 2 dextroamphetamine); 1 was being treated
with a selective norepinephrine reuptake inhibitor (atomoxetine); 1
was being treated with an anti-convulsant (levetiracetam); 2 were
being treated with anti-depressants (1 fluoxetine, 1 fluvoxamine);
and 1 was being treated with an anti-psychotic (risperidone).
However, no controls were undergoing neuropharmacologic
treatment at time of MRS. Control subjects were recruited from
local community schools. Exclusion criteria for healthy controls
included any lifetime significant medical or Axis I mental disorder
based upon the KSADS or the Diagnostic Interview Schedule for
Children (C-DISC-4, Shaffer et al., 2000) interview with the
parent [96], with the following exceptions. As 4 of the ASD
subjects were being treated with stimulant medications, we
included one control subject meeting criteria for inattentive
attention-deficit disorder (9 inattentive symptoms on the DISC-
IV) and four subjects with 1–2 inattentive symptoms and 2–3
hyperactive symptoms as assessed by the DISC-IV in the control
group. The samples did not differ significantly in age. Mean full-
scale IQ, assessed using either the Weschler Intelligence Scale for
Children (Weschler 1991) or the Weschler Adult Intelligence Scale
or (WASI) (Wechsler Abbreviated Scale of Intelligence – WASI)
[97], was 106.6613.5 (76–142) for the sample with ASD and
101.2613.6 (65–118) for the control sample. This was not a
significant difference. One control subject had full-scale IQ 65 and
therefore met a formal criterion for mental retardation. This was
an otherwise normally functioning subject who did not qualify for
any other psychiatric or developmental disorder. Exclusion of this
subject did not change the study results. All other participants in
both groups had full-scale IQ .75. The study was approved by
the UCLA Human Subjects Review Board and we obtained
written, informed consent from all subjects or from the subjects’
parents or guardians.
MRI and multi-voxel 1H MRSI were acquired contemporane-
ously at 1.5 T on a Siemens Sonata system with quadrature head
coil. No subjects were sedated at time of scan. After initial
localizer, an axial-oblique whole-brain double turbo spin-echo
(DTSE) structural MRI was acquired oriented parallel to the genu-
splenium line as seen in the sagittal plane. This was followed by a
sagittal T1-weighted high-resolution whole-brain SPGR structural
MRI volume (TR/TE = 25/11 ms, NEX = 1, partition thickness
= 1.2 mm contiguous, in-plane resolution = 161 mm2). Water-
suppressed 1H MRSI (PRESS, TR/TE = 1500/30 ms, NEX = 8,
slab thickness = 9 mm, in-plane resolution = 11611 mm2; Fig. 4)
was acquired in the plane of the DTSE. The ‘‘PRESS box’’ –
acquisition volume from which usable spectra could be obtained –
measured 464 voxels in cross-section in every subject. The
nominal voxel size was 9 mm 611 mm 611 mm < 1.1 cc.
Identical voxel positioning procedures were employed for subjects
with ASD and controls by operators blinded to subject diagnosis.
The pACC PRESS box straddled the longitudinal midline and
was positioned with its posterior end at the rostrum of the corpus
callosum, set just far back enough to prevent the anterior end of
the box from contacting extracranial tissue. The slab was also
centered dorsoventrally about the callosal rostrum. The lateral-
mesial (left-right) position of the grid was moved to minimize
differences in voxel composition. In particular, where subject
anatomy permitted, the gridlines were positioned such that voxels
lay entirely in left or entirely in right pACC and also such that
gray-matter content of voxels generally was maximized. Thus,
posterior voxels of this box sampled pACC and anterior voxels
sampled mesial superior frontal cortex. Lateral voxels sampled
prefrontal white matter. This PRESS scan was immediately
followed by non-water-suppressed PRESS MRSI (NEX = 1,
otherwise identical parameters). Finally, the whole-brain SPGR
was repeated.
Operators were blinded to subject identity during MRI and
MRSI post-processing. Offline, for each subject, the two whole-
brain SPGR volumes were coregistered to each other and
averaged together to enhance signal-to-noise ratio. The averaged
SPGR was then manually edited to remove non-brain tissue.
Automated programs were used to correct for magnetic field
inhomogeneities [98], realign the images into a standard
orientation using rigid-body transformations [99], and segment
the volume into whole-brain masks representing gray matter,
white matter, and CSF using a partial-volume correction method
[100]. The masks were reverse-transformed to the subject’s native
space and binarized.
Siemens MRSI data were processed automatically with
LCModel [81]. LCModel yielded absolute levels in Institutional
Units (IU) scaled to water for the five major metabolite peaks.
Numerous weaker resonances, in particular lipids and macromol-
ecules, were included in the fit.
The UCLA MRSI Voxel Picker (MVP) version 1.0 software
suite [101,102] was used for MRI/MRSI co-processing. The
averaged SPGR volume and its gray-matter, white-matter, and
CSF component masks were imported into MVP together with the
MRSI raw data file and LCModel output. MVP reconstructed the
subject’s SPGR and displayed it in a guided user interface (GUI) in
register with the corresponding MRSI PRESS volume in its plane-
of-acquisition. MVP similarly reconstructed the whole-brain gray-
matter, white-matter, and CSF binary masks; computed the
volume% gray matter, white matter, and CSF in each MRSI
voxel; and corrected the LCModel-derived levels of each
metabolite for voxel CSF content. Metabolite levels were not
corrected for T1- or T2-relaxation. Quality control of MRSI
spectra was also implemented automatically by MVP, supple-
mented by operator inspection. Only spectra that showed a
linewidth #0.1 ppm and a signal-to-noise ratio $3 were used for
subsequent analysis. Furthermore, within each voxel, MVP
Anterior Cingulate Glutamate in ASD
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retained only those metabolite values that LCModel considered
reliable (SD #20%). Voxels were selected by the operator on the
MVP GUI in left and right hemispheres for pACC and for
adjacent left and right prefrontal white matter. Within each
structure, MVP averaged together the metabolite levels and tissue
composition for all voxels that contained $50 vol% gray matter
($70 vol% white matter for the white-matter regions), which
satisfied the foregoing quality-control criteria.
Data were rank-transformed for non-parametric statistical
analyses. MRSI voxel tissue composition (volume% gray matter,
white matter, CSF) was compared between groups using
independent T-test. To account for multiple comparisons,
omnibus testing of CSF-corrected metabolite levels was performed
prior to between-group regional comparisons. In particular, for
each metabolite a repeated-measures ANCOVA (R-ANCOVA)
was performed with Hemisphere (two levels: left, right) as within-
subjects factor and Group (two levels: autism, control) as between-
subjects factor. Tissue composition was included as covariate in
the event of significant differences between groups. For metabo-
lites for which R-ANCOVA yielded a significant main effect or
interaction involving Group, post-hoc ANCOVA was performed
comparing the between-group metabolite levels in each individual
region, with volume% tissue composition included as covariate as
appropriate.
As a further test of the possible influence of white-matter
intrusion on pACC results, metabolite levels were compared
between groups in adjacent left and right prefrontal white matter
using independent T-test, to see if the same metabolite effects were
present as in the cortex. Criterion for statistical significance for all
tests was p,0.05.
Results and Discussion
MRSI voxel tissue compositions are listed in Table 4. In both
left (p,0.0005) and right (p,0.01) pACC volume% gray matter
was significantly higher in subjects with ASD than in controls.
Contrary to expectation, mean voxel volume% gray matter was
10–20% lower and mean voxel volume% white matter was 5–10%
higher than the corresponding values in Experiment 1. The
Experiment 1 strategem of varying MRS voxel dimensions was
apparently more effective than using smaller MRSI voxels of a
fixed size in maximizing gray-matter content. Based on these
findings, volume% gray and volume% white matter were included
as covariates in between-group comparisons of metabolite levels.
Fig. 4 shows a sample MRSI spectrum from left pACC. An
appreciable Glx peak is visible next to the tNAA peak at
2.01 ppm. Table 4 lists group-mean CSF-corrected LCModel-
derived metabolite values in left and right pACC. Omnibus R-
ANCOVA for pACC covarying volume% left and right pACC
gray matter and white matter indicated significant main effects of
Table 3. Experiment 2: Subject group characteristics.
group gender age, years full-scale IQ medication
ASD 19 male, 7 female 10.263.3 (6.1–17.5) 106.6613.5 (76–142) 5 stimulants, 1 anti-convulsant, 2 anti-
depressants, 1 anti-psychotic
Typically developing 11 male, 5 female 11.863.0 (7.3–16.6) 101.2613.6 (65–118) none
values for age and IQ are group mean 6 standard deviation (range).
doi:10.1371/journal.pone.0038786.t003
Figure 4. (Right three panels) MRI sections showing positioning of axial-oblique (parallel to genu-splenium line in sagittal plane)
proton magnetic resonance spectroscopic imaging (1H MRSI, TR/TE =1500/30 ms) slab (green grid). The PRESS acquisition volume (white
box) sampled bilateral pregenual anterior cingulate cortex (pACC, posterior mesial voxels), mesial superior frontal cortex (anterior mesial voxels) and
laterally adjacent white matter (lateral voxels). (Left panel) sample spectrum from left pACC voxel selected in blue. The white trace depicts the raw
data, the red trace is a summary fit provided by the Siemens Sonata software. This is superseded by a definitive fit provided by LCModel. An
appreciable Glx peak is evident. Experiment 2.
doi:10.1371/journal.pone.0038786.g004
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Group for tNAA (F(1,26) = 5.4, p,0.05) and Cr (F(1,26) = 7.2,
p,0.05) and a significant Group-by-Hemisphere interaction for
Glx (F(1,24) = 4.6, p,0.05). In post-hoc ANCOVA covarying
volume% gray and white matter, in right pACC only, Glx (9.5%,
F(1,33) = 4.9, p,0.05), Cr (6.7%, F(1,35) = 6.5, p,0.05), and
tNAA (10.2%, F(1,35) = 8.2, p,0.01) were significantly higher in
the sample with ASD than in the control sample (Fig. 5). Glx was
above the control mean for 16 of 23 subjects with ASD. Similar
Glx elevation was observed when left and right pACC metabolite
levels were averaged together. Upon removing subjects on
medication, a notable Glx excess (8.5%) was still present in right
pACC in the sample with ASD, though (perhaps due to the
smaller number of subjects) this was no longer statistically
significant. MRSI metabolite levels were also interrogated in left
and right prefrontal white matter proximally lateral to the pACC
in the same slab. In the sample with ASD, mean volume% white
matter in these voxels was 86.3% 64.6% (77.7–95.6%) on the left
and 83.5% 66.1% (74.3–96.2%) on the right; for the control
sample, the values were 84.9% 69.4% (70.0–99.5%) on the left
and 79.9% 65.6% (71.6–87.5%) on the right. There were no
significant between-group differences in volume% white matter,
gray matter, or CSF in these white-matter regions. In the sample
with ASD, Glx in these voxels was 9.262.1 IU (6.0–13.5 IU) on
the left and 9.761.4 IU (7.8–12.6 IU) on the right; for the control
sample, the values were 9.560.9 IU (8.2–10.7 IU) on the left and
10.761.7 IU (8.5–13.2 IU) on the right. There were no significant
between-group differences in Glx, Cr, tNAA or any other
metabolite in these white-matter regions.
This multi-voxel MRS investigation of glutamatergic metabo-
lites in pACC yielded three major findings in the right pACC only:
1) Glx was higher in subjects with ASD than in typically-
developing control subjects, 2) Cr was higher in subjects with
ASD, and 3) tNAA was higher in subjects with ASD. These
findings reinforce the notion from Experiment 1 that pACC
metabolism is abnormal in ASD, with hyperglutamatergia as one
feature. Abnormalities in Cr and tNAA metabolism are less
Table 4. Experiment 2: Voxel tissue content and proton
magnetic resonance spectroscopic imaging (1H MRSI)
metabolite levels in bilateral pregenual anterior cingulate
cortex (pACC) voxel.
ASD Healthy Control
mean ± SD range mean ± SD range
Left pregenual Anterior Cingulate Cortex
vol% GM 77.7±3.8*** 69.5–90.2 67.669.5 51.9–85.5
vol% WM 13.265.4 5.1–23.4 17.268.7 8.7–41.9
vol% CSF 9.165.6 1.6–19.1 8.666.7 0.6–21.2
tNAA 7.761.0 5.6–9.2 7.061.0 4.6–8.3
Glx 13.661.8 10.0–17.6 13.461.5 11.5–17.3
Cr 5.360.9 3.6–6.9 5.060.7 3.9–6.2
Cho 1.560.3 1.1–2.1 1.460.2 1.0–1.8
mI 4.260.7 2.8–5.5 3.960.8 2.4–5.2
Right pregenual Anterior Cingulate Cortex
vol% GM 75.9±3.5** 69.4–82.8 70.268.7 58.0–90.3
vol% WM 14.864.4 6.9–24.6 18.7612.0 2.8–37.7
vol% CSF 8.963.8 2.8–16.9 10.467.1 0.7–22.1
tNAA 7.6±1.0** 5.1–10.0 6.961.4 5.4–9.2
Glx 14.5±2.2* 9.2–19.1 13.262.6 9.5–17.5
Cr 5.4±0.9* 3.9–7.3 5.061.0 3.9–7.1
Cho 1.560.3 1.0–2.3 1.460.3 1.1–1.9
mI 4.160.7 2.7–5.5 3.961.1 2.9–6.6
*p,0.05 vs. controls ANCOVA following omnibus R-ANCOVA both covarying
vol% GM and WM on rank-transformed (non-parametric) data. Abbreviations as
in Table 2.
doi:10.1371/journal.pone.0038786.t004
Figure 5. LCModel-derived absolute metabolite levels in
Institutional Units (IU) corrected for voxel CSF-content for
subjects with ASD (red triangles) and healthy controls (green
squares) in right pACC. Horizontal bars denote group means. Values
are shown for glutamate + glutamine (‘‘Glx’’; top), creatine +
phosphocreatine (middle), and N-acetyl-aspartate + N-acetyl-aspartyl-
glutamate. Note elevations of all three metabolites in subjects with
ASD. *p,0.05, **p,0.01 (ANCOVA following R-ANCOVA of rank-
transformed, therefore non-parametric data.) Experiment 2.
doi:10.1371/journal.pone.0038786.g005
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reliably supported. All three effects may be lateralized to the right
pACC.
The first finding was elevated Glx in right pACC in ASD. As
with the finding from Experiment 1 of elevated Glx in midline (left
+ right) pACC, this result supports hyperglutamatergic theories of
ASD. All of the arguments advanced in the Discussion of
Experiment 1 regarding the possible mechanisms and conse-
quences of this hyperglutamatergia also apply here.
The second finding was elevated Cr in right pACC in ASD. As
in the Discussion of the diminished Cr found in Experiment 1, this
could be a sign of inefficient utilization of local cell energy, only
with an aberration in the opposite direction in this instance.
The third finding was elevated tNAA in right pACC in ASD.
An elevation in tNAA = NAA + NAAG may represent higher
levels of NAA, of NAAG, or of both. Local elevations of NAA
could result from multiple mechanisms, including faster astrocyte-
membrane decomposition of NAAG into Glu and NAA [85],
slower oligodendrocyte-membrane degradation of NAA into
acetate and aspartate [103,104], slower intraneuronal synthesis
of NAAG out of NAA and Glu [105], and/or faster intraneuronal
NAA synthesis out of aspartate and acetyl-CoA [103,106].
Elevations of NAAG could result from faster pre-synaptic vesicular
release [84], slower astrocytic decomposition into Glu and NAA,
and faster neuronal synthesis out of NAA and Glu. Additionally,
some genetic studies associate ASD with the SLC25A12 gene
coding for the aspartate/glutamate carrier aralar1 in the
mitochondrial membrane [19–23]. This carrier transports aspar-
tate ions across the membrane out of the mitochondrion into the
cytoplasm in exchange for Glu ions that leave the cytoplasm and
enter the mitochondrion. Inside the mitochondrion, aspartate may
be consumed by NAA synthesis and Glu may be consumed by the
Krebs Cycle. Thus, any genetic variant that decreases transport
efficiency and/or mitochondrial membrane density of aralar1 (if
such be the case in ASD) could contribute to simultaneous
elevation of Glx and tNAA, as seen in Experiment 2.
1H MRS has linked glucose metabolic rate to tNAA [107] and
to Glx [108], while 13C MRS has linked glucose metabolic rate to
NAA [109] and to Glu [110]. Among the factors underlying this
linkage may be direct transport of water generated in energetic
catabolism out of the neuron by NAA and NAAG [111,112] and/
or regulation of neuronal and glial water content by osmolytic
NAA and Glu [87]. Thus, elevations of all three metabolites (Glx,
Cr, and tNAA) may be associated with disturbed brain energy
metabolism in ASD. The lack of significant between-group
differences in the levels of these three metabolites in proximal
prefrontal white matter suggests that the effects are characteristic
of local cortex and not white matter.
Each of the three metabolite elevations was apparent only in the
right pACC. These findings join prior neuroimaging reports of
lateralized effects of ASD within the anterior cingulated
[42,53,60–62], specifically to right anterior cingulate (as reviewed
by Mundy) [72] in some cases. It is possible that, with more
subjects, effects might be observed in both cerebral hemispheres.
Some subjects with ASD but no controls were receiving
psychotropic medication at time of scan. MRSI voxels contained
significantly more gray matter in subjects with ASD than in
controls, although voxel tissue composition was covaried for and
results of a targeted sampling of high white-matter voxels appeared
to rule-out the possibility that observed effects were due to
between-group differences in voxel tissue content.
Discussion
The small pilot investigation, Experiment 1, indicated elevated
Glx in pACC in ASD. A larger follow-up study, Experiment 2, in
which the sample with ASD and the control sample were now
better matched for gender and IQ again found elevated Glx in
ASD, albeit restricted to right pACC. Thus, two separate studies
using independent samples of children with ASD and controls and
scanning on two different systems (GE, Siemens) both support the
idea of pACC hyperglutamatergia in ASD.
As discussed in our review (Levitt et al., in press) [113], prior
MRS studies reporting Glu or Glx in ASD have yielded mixed
results, presumably due to differences in subject samples and MRS
methods. Using rigorous MRSI methods, Friedman et al. (2003,
2006) [31,32] found no effects of ASD on Glx in the cingulate.
Unfortunately, these authors do not specify which subregion(s) of
the cingulate they sampled. Also, all the subjects with ASD in their
study underwent propofol sedation at time of scan, whereas that
was the case for only one subject in Experiment 1 and for none in
Experiment 2. Shulman et al. (2003, 2009) point out that brain
energetic metabolism, and thence the rate of Glu-Gln cycling and
thereby possibly Glx levels, is intimately related to anesthesia-
induced level of consciousness [114,115]. Finally, the subjects in
Friedman et al. (2003, 2006) were considerably younger (,5 years
old) than ours. Anatomic neuroimaging suggests differences
between ASD in early and later childhood; for example, the
well-known observation of brain overgrowth in ASD between 2–
4 years [116,117] that arrests or normalizes in later childhood and
adolescence [118,119]. Changes in regional neurometabolite levels
in the developmental course of ASD may similarly underlie
differences between our Glx findings and those of the Seattle
Group. DeVito et al. (2007) [28] obtained below-normal Glx and
tNAA diffusely in cortical gray matter in subjects with ASD. In
particular, endpoint values were extrapolated from linear plots of
metabolite levels sampled from voxels across entire cerebral lobes.
Hence, it is not clear what levels of this metabolite were locally in
pACC. Also, their TE of 135 ms leaves a rather small Glx signal
that is perhaps less reliable than the signals of other metabolites.
Sampling the amygdala-anterior hippocampus, Page et al. (2006)
[47] measured elevated Glx in their sample with ASD. Experi-
ments 1 and 2 are not strictly comparable with these prior studies
as the latter did not specifically target the pACC using short-TE
(25–30 ms) spectroscopy; to that extent, the present findings are
novel. Using methods similar to our, Bernardi et al. (2011) [53]
observed depressed Glx in right pACC, the opposite of the present
findings, but in adult subjects with ASD. On the one hand, these
opposite findings may reflect differences between adults and
children. On the other hand, metabolite levels in our study are
CSF-corrected and take account of MRSI voxel tissue composition
while Bernardi et al. (2011) [53] do not provide this information.
As metabolite levels vary between tissue types, it is possible that
metabolite effects in Bernardi et al. (2011) [53] are confounded
with intersubject variation in voxel tissue composition. Thus, while
our studies of ASD offer anatomically highly targeted assays of
pACC metabolite levels at short-TE accounting for voxel tissue
composition, no previous study we are aware of offers comparable
methodological rigor in the same age range (middle-childhood to
adolescence).
Hence, we think that our two experiments add support to the
notion that hyperglutamatergia exists at least in pACC and at least
in middle to late childhood and adolescence in ASD. To
determine whether this applies also in early childhood, a
subsampling of the Seattle data within the pACC portion of their
MRSI slab might be helpful; a more stringent and more
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challenging test would be to acquire from the region in non-
anesthetized children, perhaps while sleeping or using very rapid
pulse sequences. To determine whether hypo- or hyperglutama-
tergia applies in pACC in adults with ASD, results of an analysis of
the Bernardi et al. (2011) data taking account of voxel tissue
composition might be helpful.
The findings of hyperglutamatergia in our studies are generally
consistent with recent broader theories of autistic spectrum
disorders that emphasize an imbalance in cortical excitation vs.
inhibition [120,121]. Elevated glutamatergic metabolism, as seen
in the present results, may be a consequence of deficient central
GABAergic inhibition, as proposed in these theories. Based on
human post-mortem and genetic and rodent ASD model
investigations, inadequate GABAergic inhibition may have mul-
tiple developmental causes including underexpression of the
GAD65 and GAD67 enzymes (that synthesize GABA from Glu),
atypical GABAA receptor subunit composition, and failure of
neuroligin and neurexin synaptic binding proteins to appose post-
synaptic GABA receptors precisely to presynaptic release sites. In
the past few years, translational neuroscience has been making a
mounting case for hypofunctioning of brain GABAergic systems
ASD that could lead to excess brain glutamatergic metabolism.
Whereas Experiment 1 found diminished pACC Cr in the
sample with ASD, Experiment 2 found elevated Cr in right
pACC. Thus, abnormal Cr in pACC in ASD, if it does exist, is
more variable and harder to reproduce than abnormal Glx. This
variability might reflect unstable local cell energetics that induce
an expanded creatine-phosphocreatine ATP buffer in some
subjects and a contracted buffer in others. Page et al. (2006)
[47] also observed elevated Cr in amygdala-hippocampus in ASD,
and Levitt et al. (2003) [42] observed effects of ASD diagnosis on
Cr in occipital cortex and caudate, so there is precedence for
abnormal Cr in ASD, albeit in other brain regions.
Elevated tNAA was found in pACC in ASD in Experiment 2
only. Again, abnormal tNAA in ASD may be harder to reproduce
than elevated Glx. In prior work, Oner et al. (2007) [46] registered
higher tNAA/Cr and tNAA/Cho in right anterior cingulate cortex
in subjects with Asperger’s syndrome than in controls and Fujii
et al. (2010) [33] found lower tNAA/Cr in anterior cingulate in
subjects with autism than in controls. Interpretation of these results
is partially obscured by normalization to Cr, which itself may vary,
but they do suggest heterogeneous effects of ASD on tNAA. In
other brain regions (reviewed in Levitt et al, in press) [113],
investigators have often found below-normal tNAA or its ratios in
ASD, although findings of above-normal and no difference also
exist. How plausible is a local elevation of tNAA in the pACC? In
addition to the above-cited MRS results, data from recent fMRI
and hybrid fMRI-MRS experiments do, in fact, strongly suggest a
special role for the pACC in ASD and autistic symptomatology.
The pACC, for example, was one of the few brain regions
demonstrating significant effects of ASD diagnosis in a recent
metaanalysis of fMRI studies [66]. Working in healthy subjects,
the same researchers related fMRI functional connectivity with the
pACC with elevated levels of autistic traits [65]. Also in healthy
controls, Duncan et al. (2011) [76] found correlations localized to
pACC between MRS Glx and an fMRI effect related to subject
empathy, low empathy being a common symptom of ASD.
Finally, elevated intensity was observed in at-risk carriers of an
autism-associated CNTNAP2 allele in pACC [75]. These and
other neuroimaging results give ample evidence for focal effects of
ASD diagnosis and autistic traits and autistic symptoms in the
pACC. It is therefore not surprising to find MRS metabolic effects
particular to that brain region.
Experiment 2 alleviated several but not all limitations of
Experiment 1. Both studies were still conducted at low-field (1.5
T) and expressed their results as Glx rather than as Glu and Gln
separately. Based on low field strength and, in the case of MRSI,
small voxel size, our quality control procedures used the standard
20% SD criterion of the LCModel fitting package and a SNR cut-
off of 3 for MRSI and 5 for single-voxel MRS. Although some
spectroscopists might prefer stricter cut-offs, working with these
values we found that individual metabolite peaks were typically
readily identified by eye and easily fit by automated routines. Also
single-subject data quality was frequently higher than the cut-off
values. In neither study was it possible to match between-group
voxel tissue-composition thoroughly (although differences were
dealt with through statistical covariates and co-sampling proximal
white matter). Efforts to match tissue composition may have been
aggravated by putative effects of ASD on anterior cingulate
cortical volume or thickness [58–61]. Future MRS and MRSI
studies at 3 T will allow smaller, hopefully more tissue-pure voxels
and also better spectral segregation of Glu and Gln. Regarding the
latter, better segregation might also be achieved by acquiring
spectra at TE = 80 ms, thought to be optimal for quantifying Glu
[122–124]. Future investigations should also include MR relaxa-
tion studies, as autism may affect metabolite and water relaxation
times [31,125]. Finally, in both Experiments, several subjects with
ASD were undergoing treatment with psychotropic medication at
time of scan. Ideally, one would test only drug-naı¨ve subjects,
although, given clinical realities, this can be difficult to achieve on
a practical time scale. These limitations notwithstanding, the
present findings suggest that Glx is elevated locally in pregenual
anterior cingulate cortex in subjects with ASD. This elevation,
combined with less certain effects of autism on Cr and tNAA may
reflect disturbances of cell-energy metabolism.
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